RE:Clouds comingImpossible to say if it’s good new or bad new. On the good side we don’t know if Epanova will be ever commercialize so less concurrence and since the mixture of Acasti is very different with the phospholipid we also never know if Acasti would be required a long CVOT, but on the other side I must agree that would had prouve the class effect.
in any case Acasti angle is the diabetics.
We must AZN results for any conclusion.
GLTA